Biovie (BIVI) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Biovie in October 2026.
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Biovie (BIVI) Stock Forecast
Analyst price target, next 12 months
$5.00
+242.5% vs today's $1.46
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Biovie have a consensus 12-month target of $5.00, above the current price of $1.46.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Jun 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying BIOVIE INC's stock with a target price of $5, indicating good potential growth.
Financial Health
BIOVIE INC has decent cash flow and book value, indicating stable financial standing.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
